New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC. This is not an official program of the American Association for Cancer Research Annual Meeting.
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with urothelial cancer.
Upon completion of this activity, participants should be able to:
- Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, and patient and disease characteristics
- Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
- Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
- Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
- Describe the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
- Discuss ongoing clinical trials investigating targeted systemic therapies and ICI-based combinations for patients across the UC disease spectrum
Daniel P. Petrylak, MD, PhD
Yale Cancer Center
Matthew I. Milowsky, MD
UNC Lineberger Comprehensive Cancer Center
Jonathan E. Rosenberg, MD
Memorial Sloan Kettering Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE/CPE activity:
Matthew I. Milowsky, MD, has disclosed that he has received consulting fees from BioClin Therapeutics and research funding paid to his institution from Acerta Pharma, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cerulean Pharma, Clovis, Constellation Pharmaceuticals, Incyte, Innocrin Pharma, Inovio Pharmaceuticals, Jounce Therapeutics, Medimmune, Merck, Roche/Genentech, Seattle Genetics, Syndax, X4 Pharmaceuticals.
Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myer Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen; funds for research support from Ada Cap, Astellas, AstraZeneca, Bayer, Bristol Myer Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics; and has ownership interests/investments in Bellicum.
Jonathan E. Rosenberg, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen Merck, Pharmacyclics, Pfizer, Roche/Genentech, and Seattle Genetics, and research funding from Astellas, AstraZeneca, Bayer, QED Therapeutics, Seattle Genetics, and Roche/Genentech, and faculty honorarium from Chugai.
The activity planning staff listed below disclose no relevant financial relationships:
CCO: Kristen Rosenthal, PhD; Timothy A. Quill, PhD; Gordon Kelley; Jason J. Everly, PharmD, BCOP, CHCP; June Wasserstrom; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The CCO planning staff listed below discloses the following relevant financial relationships:
Jim Mortimer: spouse/partner has ownership interest (stock) in AstraZeneca
The NCCN clinical staff listed below discloses no relevant financial relationships:
Lisa Gurski, PhD; Rashmi Kumar, PhD; Angela Motter, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-20-070-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 1.50 AAPA Category 1 CME credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 Participation